ライフサイエンスコーパス: IFN-alpha

1 IFN-alpha and systemic corticosteroids, compared with no

2 IFN-alpha impairs insulin-mediated NO production, and al

3 IFN-alpha increased HLA-DR, CD80, CD86, and PD-L1 expres

4 IFN-alpha levels were measured in supernatants, and mRNA

5 IFN-alpha limits CHIKV replication and dissemination, wh

6 IFN-alpha production was inhibited only in cells infecte

7 IFN-alpha significantly impaired NO production in insuli

8 IFN-alpha significantly increased depression symptoms (H

9 IFN-alpha treatment also led to enhanced neutrophil adhe

10 IFN-alpha-induced signaling was impaired in the patient

11 IFN-alpha-mediated inhibition of IL-12 production, rathe

12 IFN-alpha/-beta have very low basal expression levels bu

13 (PFS) of bevacizumab or interferon alfa-2b (IFN-alpha-2b) added to octreotide among patients with ad

14 apeutic efficacy of the AAV-IFN-alpha or AAV-IFN-alpha fused to apolipoprotein A-1 vectors in experim

15 hylactic and therapeutic efficacy of the AAV-IFN-alpha or AAV-IFN-alpha fused to apolipoprotein A-1 v

16 ription of IFN-stimulated genes (ISGs) after IFN-alpha treatment.

17 Interferon alpha (IFN-alpha) and IFN-beta are type I IFNs that are induced

18 ated by others and us that interferon alpha (IFN-alpha) treatment of hepatocytes induced a prolonged

19 n of inflammatory cytokine interferon alpha (IFN-alpha).

20 Interferon-alpha (IFN-alpha) can suppress production of T-cell polarizing

21 ety of corticosteroids and interferon-alpha (IFN-alpha) in adults with such conditions.

22 mycin (mTOR) signaling and interferon-alpha (IFN-alpha) production by plasmacytoid dendritic cells.

23 ver, a prolonged, elevated interferon-alpha (IFN-alpha) response is associated with a negative diseas

24 hird of patients receiving Interferon-alpha (IFN-alpha) treatment for Hepatitis-C develop major depre

25 interferons, particularly interferon-alpha (IFN-alpha), play a vital role in the host's anti-viral d

26 t of myeloid cells that are resistant, in an IFN-alpha/beta-dependent manner, to VEEV-induced macromo

27 ] vs 12.0 pg/ml [12.0, 126.7]; p = .03), and IFN-alpha (5.1 pg/mL [5.1, 5.1] vs 5.1 pg/ml [5.1, 26.3]

28 es toll-like receptor (TLR)-9 activation and IFN-alpha production.

29 t is differentially utilized by IFN-beta and IFN-alpha for signal transduction.

30 over, CVB3 did not induce IFN-alpha/beta and IFN-alpha/beta-stimulated genes in control cardiomyocyte

31 s) was necessary for increased chemokine and IFN-alpha secretion in response to the parasite.

32 OD (P = .0285), and between the control and IFN-alpha groups for the OD (P = .0424) and worse eye (P

33 Pathway analysis indicated that ESR1 and IFN-alpha may be particularly influential transcription

34 lation with myxovirus 1 (MX1) expression and IFN-alpha release.

35 ation by upregulation of CD86 expression and IFN-alpha secretion.

36 with strong downregulation of IFN-gamma and IFN-alpha gene signatures that were reversed by treatmen

37 eutralizing antibodies against IFN-gamma and IFN-alpha/beta receptor subunit 1, and their cellular so

38 We observed elevated levels of ISGs and IFN-alpha in blood of symptomatic COPA patients.

39 Using both wild-type C57BL/6 mice and IFN-alpha/beta receptor-deficient mice, we show that NS1

40 ve increases in proinflammatory proteins and IFN-alpha in distal airways.

41 4815; TT) is associated with spontaneous and IFN-alpha-dependent cure of hepatitis C virus infection.

42 s essential for TLR9-driven suppression, and IFN-alpha cannot compensate for impaired IFN-gamma signa

43 eurons revealed normal responses to TLR3 and IFN-alpha/beta stimulation but abnormal responses to HSV

44 phtheria toxin receptor (DTR) transgenic and IFN-alpha receptor 1-deficient mice, as well as purified

45 omalizumab treatment increases pDC antiviral IFN-alpha responses in inner-city children with asthma.

46 ) and interleukin-6 (IL-6) mRNAs, as well as IFN-alpha, IFN-beta, and TNF-alpha mRNA levels induced b

47 B, elevation of pDC survival, and attenuated IFN-alpha and TNF-alpha production.

48 nscription activity and partially attenuated IFN-alpha suppression of cccDNA transcription.

49 ed in human cells ectopically expressing bat IFN-alpha and IFN-beta.

50 ing to suppression of interferon alpha/beta (IFN-alpha/beta) production.

51 studies using a monoclonal antibody to block IFN-alpha/beta receptor (IFNAR) signaling in humanized m

52 In support of our a-priori hypothesis, both IFN-alpha and anti-TNF significantly modulated amygdala

53 . aureus was observed after exposure to both IFN-alpha and -gamma, whereas IFN-gamma appeared to inhi

54 effect of Vpu was shown to be attenuated by IFN-alpha treatment.

55 ctivation of regulatory pathways in ILC2s by IFN-alpha.

56 ociated histones similar to those induced by IFN-alpha treatment.

57 ncy of up to 8 Hz, which was not mimicked by IFN-alpha or IL-17 exposure.

58 contrast, SARS-CoV-1 was restricted only by IFN-alpha in these cell lines.

59 this failure could be effectively rescued by IFN-alpha receptor blockade.

60 fection in trans via coculture with CD169(+) IFN-alpha-treated DCs restored infection, suggesting tha

61 In the spinal cord IFN-alpha was primarily expressed by astrocytes.

62 e possibility of exploring such short-course IFN-alpha treatments for the enhancement of effector cel

63 nt experiments were carried out to determine IFN-alpha resistance, replication fitness, and viral pro

64 In this study, we attempted to determine IFN-alpha susceptibility and productivity of infectious

65 ronal signaling contributes to these diverse IFN-alpha/beta functions is poorly understood.

66 potential of sustained delivery of low-dose IFN-alpha for the treatment of MS and likely other T cel

67 The sustained delivery of such low-dose IFN-alpha resulted in immunomodulatory effects, consisti

68 Mice lacking either IFN-alpha or IFN-beta developed severe clinical disease

69 Suppression of either IFN-alpha or TNF-alpha production capacity was associate

70 and fibrosis, which do not depend on either IFN-alpha/beta receptor signaling or mixed lineage kinas

71 ation behind the failure at targeting either IFN-alpha or the type 1 IFN receptor itself.

72 ckout BMDMs, and knockout BMDMs had elevated IFN-alpha/beta production compared with control BMDMs.

73 Bronchial epithelial IFN-alpha/beta expression and numbers of subepithelial I

74 Lower epithelial IFN-alpha/beta expression was associated with adverse cl

75 Lower epithelial IFN-alpha/beta expression was related to greater viral l

76 -molecular-weight/LyoVec and LPS to evaluate IFN-alpha and TNF-alpha production capacities (RIG-I and

77 osed to patient plasma samples or exogeneous IFN-alpha.

78 and artificial stimuli, as well as exogenous IFN-alpha, and was PI3K dependent.

79 Finally, exogenous IFN-alpha did not substantially protect cardiomyocytes a

80 lication with one or more doses of exogenous IFN-alpha or -gamma before or during the first few days

81 tained replication even exposed to exogenous IFN-alpha.

82 bepithelial monocytes/macrophages expressing IFN-alpha/beta in asthmatic patients during infection.

83 blood sampling before and after their first IFN-alpha (4-h) or anti-TNF (24-h) injection and follow-

84 Vs, we developed knockout (KO) HIE lines for IFN alpha and lambda receptors and the signaling molecul

85 IRF3, transcription factor was critical for IFN-alpha/beta induction in vitro and in sera of mice.

86 nd the transcription factors responsible for IFN-alpha/beta induction.

87 and human lupus studies revealed a role for IFN-alpha in vascular abnormalities associated with impa

88 Our study uncovers a pathogenic role for IFN-alpha/-beta in facilitating autoimmune toxicity duri

89 Condensates formed from IFN-alpha-induced endogenous MxA also displayed tonicity

90 oreover, encephalitogenic T lymphocytes from IFN-alpha-treated mice re-exposed to the myelin oligoden

91 Furthermore, IFN-alpha enhanced global CP CD8(+) T cell cytokine resp

92 IL-13, IL-6, IL-12, interferon (IFN)-gamma, IFN-alpha, IL-2, IL-2 R, IL-8, macrophage inflammatory p

93 by PapMV in the absence of C3 induced higher IFN-alpha production, resulting in superior immune cell

94 jectives of this study were to determine how IFN-alpha promotes endothelial dysfunction in SLE, focus

95 ting the cognate type I IFN receptor (type I IFN alpha/beta receptor [IFNAR]) to interrupt IFN signal

96 In addition, protein levels of both type I IFN-alpha (P < 0.0001) and beta (P = 0.002) were signifi

97 ver, significant associations between type I IFN-alpha/beta protein levels with the DNA methylation s

98 Mice deficient in the type I IFN-alpha/beta receptor (Ifnar1(-/-)) and administration

99 Type I (IFN-alpha and IFN-beta) and III (IFN-lambda) interferons

100 duced higher levels of expression of type I (IFN-alpha and IFN-beta) and type III (IFN-lambda1 to IFN

101 ties of the antiviral interferons of type I (IFN-alpha) and type III (IFN-lambda) against SARS-CoV-2

102 Network analyses identified IFN-alpha, IFN-beta, IL-1RI and TNF-alpha as combined bi

103 ts, recipients were treated with type 1 IFN (IFN-alpha/beta).

104 e I interferons (IFNs), including alpha IFN (IFN-alpha) and IFN-beta, potently suppress HIV-1 replica

105 Type I IFN (IFN-alpha/beta) and type III IFN (IFN-lambda) function a

106 Type I IFN (IFN-alpha/beta) controls systemic replication, and type

107 YFV NS5 requires the presence of type I IFN (IFN-alpha/beta) for its engagement with human signal tra

108 but not mouse STAT2 (mSTAT2), a type I IFN (IFN-alpha/beta) pathway component.

109 The type I IFNs (IFN-alpha and -beta) are important for host defense agai

110 We sought to understand how type I IFNs (IFN-alpha and IFN-beta) might act directly on nociceptor

111 Type I IFNs (IFN-alpha/beta) are induced in inflammatory conditions a

112 rium that induces expression of type I IFNs (IFN-alpha/IFN-beta) during infection.

113 Type I interferons (IFNs) (IFN-alpha, IFN-beta) and type III IFNs (IFN-lambda) shar

114 eving optimal antiviral responses.IMPORTANCE IFN-alpha/beta induction limits CNS viral spread by esta

115 /CCR2 signaling, which induced a decrease in IFN-alpha, but not IFN-beta expression.

116 -pseudotyped HIV-1 particles was enhanced in IFN-alpha-treated THP-1 monocytoid cells, and this enhan

117 restored parainfluenza virus 5 infection in IFN-alpha-pretreated, ISG15-deficient cells, confirming

118 ns implicate complex cooperative pathways in IFN-alpha/beta induction and responsiveness.

119 Infection of HIV-1 was rescued in IFN-alpha-treated myeloid cells via upregulation of CD16

120 P-001 induced cytokine production, including IFN-alpha from plasmacytoid dendritic cells, but only in

121 cytokine responses at age 3 years, including IFN-alpha and IL-10 responses to certain stimulants and

122 interfering RNA knockdown of Tim-3 increased IFN-alpha secretion in response to activation.

123 ed that T. gondii invaded but did not induce IFN-alpha or TNF-alpha in human pDC.

124 Moreover, CVB3 did not induce IFN-alpha/beta and IFN-alpha/beta-stimulated genes in co

125 for polyinosinic-polycytidylic acid-induced IFN-alpha/beta production and alloimmunization.

126 novel role for BCAP in promoting TLR-induced IFN-alpha production in pDC and in systemic lupus erythe

127 TLR-induced IFN-alpha production in pDC requires DOCK2-mediated acti

128 ist, and BCAP promoted TLR7 and TLR9-induced IFN-alpha production specifically in pDC.

129 ross-linking inhibits critical virus-induced IFN-alpha responses of plasmacytoid dendritic cells (pDC

130 -receptor domain-containing adapter-inducing IFN-alpha (TRIF) and nuclear factor kappaB (NF-kappaB) c

131 lar cytokine staining (ICS) in ZIKV-infected IFN-alpha/beta receptor-deficient HLA transgenic mice.

132 However, T. gondii inhibited IFN-alpha and TNF-alpha produced in response to HSV and

133 tosus patients, whereas QC and HCQ inhibited IFN-alpha equally.

134 ean 48.0 +/- 10.5 years, 21 male) initiating IFN-alpha treatment for Hepatitis-C and 30 (mean 50.4 +/

135 y, we explore the role of type 1 interferon (IFN-alpha/beta) signaling on virulence and immunogenicit

136 quired for the activity of alpha interferon (IFN-alpha) against vesicular stomatitis virus, Indiana s

137 '-deoxyuridine (5BVdU) and alpha interferon (IFN-alpha) and when the antivirals are removed, spontane

138 tested the hypothesis that alpha interferon (IFN-alpha) could improve the function of NK cells from c

139 r chronic hepatitis B, and alpha interferon (IFN-alpha) is the only available immunomodulatory drug,

140 We found that the alpha interferon (IFN-alpha) response of plasmacytoid dendritic cells (pDC

141 imulated genes (ISGs) upon alpha interferon (IFN-alpha) stimulation in cell cultures.

142 he ability of short-course alpha interferon (IFN-alpha) treatments to effectively enhance such effect

143 pregulation in response to alpha interferon (IFN-alpha) was shown to increase the susceptibility of H

144 induced the expression of alpha interferon (IFN-alpha), key cytokines, and cell adhesion molecules (

145 paracrine actions of alpha/beta interferon (IFN-alpha/beta) (type I), IFN-gamma (type II), and IFN-l

146 Alpha/beta interferon (IFN-alpha/beta) signaling through the IFN-alpha/beta rec

147 Pretreatment with type I interferons (IFN-alpha and IFN-kappa) increased IL-6 production by co

148 Type I interferons (IFN-alpha/beta) and the more recently identified type II

149 eptor 7 (TLR7)-dependent type I interferons (IFN-alpha/beta) from plasmacytoid dendritic cells as wel

150 tably, the production of type I interferons (IFN-alpha/beta), IFN-stimulated genes (PKR, OAS, Mx1, an

151 ological analysis revealed that mice lacking IFN-alpha sustained elevated infection in the infected a

152 n immune cells, including normally low-level IFN-alpha-producing cells.

153 bulk PBMC transcriptomics and transient, low IFN-alpha levels in plasma during infection.

154 cccDNA transcription and may partly mediate IFN-alpha silencing of hepadnaviral cccDNA transcription

155 erestingly, blood PDCs secreted 10-fold more IFN-alpha in response to IAV compared with tonsil PDCs.

156 ma interferon (IFN-gamma) treatment, but not IFN-alpha, -beta, or -lambda treatment, dramatically dec

157 We observed IFN-alpha/beta deficiency in the bronchial epithelium at

158 , expression of BGLF2 reduced the ability of IFN-alpha to inhibit BZLF1 expression and enhanced EBV r

159 aling; BGLF2 also counteracts the ability of IFN-alpha to suppress EBV reactivation.IMPORTANCE Type I

160 n and remaining pDC produce lower amounts of IFN-alpha in response to viral stimulation.

161 Blockade of IFN-alpha but not IFN-beta signaling using either an ant

162 g, a receptor proximal complex consisting of IFN-alpha and -beta receptors 1 and 2 (IFNAR1, IFNAR2, r

163 may partly mediate the suppressive effect of IFN-alpha on hepadnaviral cccDNA transcription.IMPORTANC

164 it inhibits the antiproliferative effect of IFN-alpha on latently infected BL cells.

165 gents to improve the therapeutic efficacy of IFN-alpha.

166 ured in supernatants, and mRNA expression of IFN-alpha pathway genes was determined by using quantita

167 tochemistry was used to detect expression of IFN-alpha, IFN-beta, and the PRRs: Toll-like receptor 3,

168 Compared with WT, the expression of IFN-alpha-stimulated genes (ISGs) was reduced in number

169 ar translocation of STAT1, and expression of IFN-alpha-stimulated genes critical for CMV immunity.

170 anisms underlying the antiviral functions of IFN-alpha in hepadnaviral infection may reveal molecular

171 bers of ISGs expressed at 12 h versus 4 h of IFN-alpha exposure in all three IFN-I signaling-deficien

172 However, the impact of IFN-alpha on mediators that induce vasodilation and modu

173 ntravaginal ZIKV infection, independently of IFN-alpha/beta or IFN-lambda signaling.

174 over a probable sex bias in the induction of IFN-alpha/beta in the cornea during HSV-1 infection.

175 s in vivo While cell-free HIV-1 infection of IFN-alpha-treated CD4(+) T cells was robustly decreased,

176 henomenon phenocopied in HIV-1 infections of IFN-alpha-treated primary monocyte-derived macrophages (

177 y type I IFN responses because inhibition of IFN-alpha/beta receptor signaling abrogated DENV-induced

178 mice and that this correlates with a lack of IFN-alpha/beta-induced YFV NS5 ubiquitination in murine

179 low SASSAD scores with the lowest levels of IFN-alpha, tissue inhibitor of metalloproteinases 1, and

180 in secretion of very high systemic levels of IFN-alpha/beta, suggesting that stress responses in resp

181 However, modulation of IFN-alpha/-beta signaling, either by functional blockade

182 The results reveal how perturbation of IFN-alpha/beta signaling in neurons can worsen disease c

183 itic cells (pDCs) are the major producers of IFN-alpha, an antiviral cytokine involved in immunomodul

184 role for C3 in regulating the production of IFN-alpha following TLR7 activation.

185 processes resulted in reduced production of IFN-alpha, IFN-gamma, IL-1beta, CCL20, and CCL8, and hig

186 Activation of TLR9 leads to production of IFN-alpha, which drives IFN-gamma production by natural

187 ignificant upregulation in the production of IFN-alpha/beta mRNAs in the lungs.

188 omain-containing 6 (ABHD6), in regulation of IFN-alpha induction in SLE patients.

189 pecific mechanism accounting for the role of IFN-alpha in immunosuppression and predicts that type I

190 this study demonstrated an essential role of IFN-alpha/beta receptor 1 (IFNAR1) specifically in neuro

191 Blocking of FDC secretion of IFN-alpha restored B cell tolerance and reduced the amou

192 or p22, inhibits the antiviral signaling of IFN-alpha, which sheds light on the enigmatic function o

193 with VEEV to identify the cellular source of IFN-alpha/beta, the timing and extent of translation and

194 mega) (13 patients), against the 13 types of IFN-alpha (36), or against both (52) at the onset of cri

195 15 mg/kg every 21 days or 5 million units of IFN-alpha-2b three times per week.

196 2 (CB2)-mediated regulatory role of 2-AG on IFN-alpha induction by pDCs.

197 B2-mediated steady-state resistive tuning on IFN-alpha induction by pDCs, thereby contributing to SLE

198 eated with an IFN-beta-blocking antibody) or IFN-alpha (IFN regulatory factor 7 knockout [IRF7-KO] mi

199 nt enrichment of rare variations in TLR3- or IFN-alpha/beta-related genes.

200 ut [IRF7-KO] mice or mice treated with a pan-IFN-alpha-blocking antibody).

201 activated T cells as sources of pathological IFN-alpha production.

202 period and correlated with increases in PBMC IFN-alpha responses.

203 icate that omalizumab treatment augments pDC IFN-alpha responses and attenuates pDC FcepsilonRIalpha

204 enza-induced PBMC and rhinovirus-induced pDC IFN-alpha responses in the presence of IgE cross-linking

205 Current treatment of CHB are Peg-IFN alpha and oral NUCs.

206 The question whether Peg-IFN-alpha is superior to NUCs and whether there is a sup

207 ential treatment of Entecavior and PEGylated IFN-alpha were recruited.

208 ronic HCV treated with combination pegylated IFN-alpha, ribavirin, and telaprevir/boceprevir.

209 al cccDNA transcription.IMPORTANCE Pegylated IFN-alpha is the only therapeutic regimen that can induc

210 ve patients, patients treated with PEGylated IFN-alpha, and patients with sequential treatment of Ent

211 In contrast to the activated phenotype, IFN-alpha inhibited Toll-like receptor-induced cytokine

212 endent fashion in the presence of 5BVdU plus IFN-alpha; and (v) 3D cultures of NPCs are less suscepti

213 sured by their decreased capacity to produce IFN-alpha.

214 frequency of pDCs expressing Tim-3 produced IFN-alpha or TNF-alpha in response to the TLR7 agonists

215 Prolonged IFN-alpha and IFN-beta responses can lead to harmful pro

216 In response to injection of purified IFN-alpha/beta or -lambda, IECs in EW-infected mice exhi

217 Patients were randomly assigned to receive IFN alpha-2b at 20 MU/m(2)/d IV for 5 days (Monday to Fr

218 IRF3, IRF7, the type I interferon receptor (IFN-alpha and IFN-beta receptor subunit 1 [IFNAR1]), T c

219 ld-type, Scga1b1-Foxo3a-/- mice show reduced IFN-alpha, IFN-beta, IFN-lambda2/3 in response to challe

220 gonucleotides in vitro and in vivo, reducing IFN-alpha secretion and the induction of IFN-stimulated

221 sfunctional pDCs and may negatively regulate IFN-alpha, possibly through interference with TLR signal

222 ts, whereas expression of WT IFNAR1 restored IFN-alpha-mediated suppression of CMV.

223 -induced translation inhibition and secreted IFN-alpha/beta despite virus infection.

224 ced IL-8 and IL-10 while CD1(-) cDC secreted IFN-alpha, IL-12 and TNF-alpha.

225 id cell cultures infected with VEEV secreted IFN-alpha/beta that increased until cell death was obser

226 0) = 220 nM) and >100-fold TLR7 selectivity (IFN-alpha EC(50) > 50 muM) was observed in human periphe

227 isease course marked by an increase in serum IFN-alpha concentration when challenged with JUNV.

228 (-/-) mice produced significantly less serum IFN-alpha than wild-type mice after injection of TLR9 ag

229 chronic hepatitis B (CHB) patients starting IFN-alpha therapy.

230 beta expression and numbers of subepithelial IFN-alpha/beta-expressing monocytes/macrophages during i

231 dies demonstrated an association of systemic IFN-alpha/beta production with myeloid cell infection ef

232 ental IFN that appeared less protective than IFN-alpha, suggesting a potential weakness in antiviral

233 We demonstrate that IFN-alpha promotes an endothelial dysfunction signature

234 nce of our research is in demonstrating that IFN-alpha and IFN-beta both have protective roles during

235 We found that IFN-alpha pretreatments lead to opposite effects, primin

236 We found that IFN-alpha signaling is transient and becomes refractory

237 We show here that IFN-alpha treatment enhanced cytokine secretion, polyfun

238 These results indicate that IFN-alpha/beta induction in vivo is IRF7 dependent and a

239 We further report that IFN-alpha, in the absence of an adjuvant, is sufficient

240 Previous studies showed that IFN-alpha therapy fails to boost virus-specific T-cell i

241 We also showed that IFN-alpha treatment of ISG15-deficient cells led to sign

242 Our data suggest that IFN-alpha treatment may potentially be used as an immuno

243 the IFN-gamma receptor (IFN-gammaR) and the IFN-alpha/beta receptor IFNAR1.

244 and disrupt complex interactions between the IFN-alpha/beta and IFN-gamma pathways in achieving optim

245 tightly regulated communication between the IFN-alpha/beta and IFN-gamma signaling pathways to optim

246 AR1 (IFNAR1*557Gluext*46), which encodes the IFN-alpha receptor signaling subunit.

247 er, the virus rapidly evolves to exploit the IFN-alpha response for its replication, spread, and path

248 r their low basal expression of genes in the IFN-alpha/beta pathway compared to glia.

249 in highly immunocompromised mice lacking the IFN-alpha/beta receptor.

250 Thus, FDCs are a critical source of the IFN-alpha driving autoimmunity in this lupus model.

251 nuclear translocation and inhibition of the IFN-alpha response was partially reversed by a deficienc

252 r7 (-/-) Tlr9 (-/-) double-knockout pDC, the IFN-alpha response to MHV68 was completely abolished.

253 o cccDNA minichromosomes and phenocopied the IFN-alpha-induced posttranslational modifications of ccc

254 We show that the IFN-alpha/beta-dependent ubiquitination of YFV NS5 that

255 feron (IFN-alpha/beta) signaling through the IFN-alpha/beta receptor (IFNAR) is essential to limit vi

256 l, we demonstrate that signaling through the IFN-alpha/beta receptor is required for inflammation-ind

257 ere mediated by direct signaling through the IFN-alpha/beta-receptor (IFNAR), as Ab-mediated blocking

258 rn recognition receptors contributing to the IFN-alpha response to MHV68 in pDC are TLR7 and TLR9, bu

259 nistration of a neutralizing antibody to the IFN-alpha/beta receptor (IFNAR) for 3 d, beginning 30 mi

260 sion patterns of factors associated with the IFN-alpha/beta pathway in different CNS resident cell po

261 We have thus identified three IFN-alpha-induced cellular proteins that suppress cccDNA

262 creasing the apoptosis rate of ILC2s through IFN-alpha production.

263 214 were allocated to bevacizumab and 213 to IFN-alpha-2b.

264 Here we show that in addition to IFN-alpha, IFN-beta and IL-27 also affect Vpu-mediated B

265 NG V154M/wild-type (WT) mice were crossed to IFN-alpha/beta receptor (IFNAR) knockout mice to evaluat

266 eAg(+)) patients respond less effectively to IFN-alpha therapy than do HBeAg-negative (HBeAg(-)) pati

267 nuclear cells from healthy donors exposed to IFN-alpha and chronic hepatitis B (CHB) patients startin

268 basal IFN signaling and hypersensitivity to IFN-alpha stimulation.

269 Chronic exposure of mice to IFN-alpha alone was sufficient to strongly suppress spec

270 ies showed that TF viruses were resistant to IFN-alpha during the very near moment of transmission, b

271 ased phosphorylation of STAT1 in response to IFN-alpha is associated with detectable activation of ST

272 ction of IFN-stimulated genes in response to IFN-alpha stimulation and it inhibits the antiproliferat

273 eas signal pathway activation in response to IFN-alpha was rapid and transient in WT MGCs, this was d

274 d HeLa cells, caused a defective response to IFN-alpha.

275 We thus hypothesized that the responses to IFN-alpha treatment of chronic hepatitis B (CHB) patient

276 Despite increased susceptibility to IFN-alpha, NT viruses produced more viral particles than

277 uent time points, they became susceptible to IFN-alpha.

278 in the CBP response including a shift toward IFN-alpha/IFN-gamma and IL-6/Jak/Signal transducer and a

279 ily in the epidermis and induced a transient IFN-alpha response.

280 3 days after CHB patients started treatment, IFN-alpha inhibited monocyte cytokine production and T-c

281 their livers than do HBeAg(-) patients upon IFN-alpha therapy.

282 HIV controller subjects, and higher ex vivo IFN-alpha-induced NK cytotoxicity after 5 wk of ART+Peg-

283 Our aim was to determine whether IFN-alpha exposure alters human antigen-presenting cell

284 However, whether IFN-alpha and anti-TNF enhance/attenuate depressive symp

285 ur study introduces a novel pathway by which IFN-alpha serves as a proatherogenic mediator through re

286 Along with IFN-alpha and IFN-beta, IFN-gamma was demonstrated to co

287 ent of gastric carcinoma and Raji cells with IFN-alpha blocked BZLF1 expression and EBV reactivation;

288 f dendritic cell (DC)-T cell cocultures with IFN-alpha upregulated CD169 expression on DCs and rescue

289 erified that potency at TLR7 correlates with IFN-alpha/beta production in human blood, whereas IFN-ga

290 he IFN subtypes during CHIKV infection, with IFN-alpha limiting early viral replication and dissemina

291 ngs raise the possibility that patients with IFN-alpha/beta-mediated conditions, including autoimmuni

292 uld be induced if cells were pretreated with IFN-alpha for longer times, presumably because of inhibi

293 ISG15-deficient cells pretreated with IFN-alpha were resistant to paramyxovirus infection.

294 Pretreatment with IFN-alpha failed to suppress CMV protein expression in p

295 et cell stimulation, even after priming with IFN-alpha.

296 ificantly modulated amygdala reactivity with IFN-alpha acutely enhancing right amygdala responses to

297 Furthermore, in NK cells stimulated with IFN-alpha, the promoter region of Rsad2 was enriched for

298 sphorylation in response to stimulation with IFN-alpha in healthy control peripheral blood mononuclea

299 STAT1 or pSTAT1 levels in cells treated with IFN-alpha, it blocks the nuclear translocation of pSTAT1

300 viruses in cultures treated with and without IFN-alpha, but the difference was significant in the cas